Blood coagulation factors as inflammatory mediators

被引:48
作者
Schoenmakers, SHHF [1 ]
Reitsma, PH [1 ]
Spek, CA [1 ]
机构
[1] Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
blood coagulation; inflammation; tissue factor; factor X and thrombin;
D O I
10.1016/j.bcmd.2004.09.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
After the first observations about blood coagulation by Hippocrates, it took until the early 1900s before the classic theory of blood coagulation was presented. As more and more other coagulation factors were discovered, the four-factor coagulation scheme became more complex, but better understood, leading to the current coagulation cascade. As during the last decade it turned out that coagulation factors might do more than just promoting (or inhibiting) blood coagulation, new scientific avenues were pursued focusing on coagulation-independent properties of individual coagulation factors. This led to the current understanding that coagulation factors, like tissue factor (TF), FVII, FX, and thrombin, are important players in inflammation, vascular development, angiogenesis, and tumorigenesis. However, the molecular mechanism by which coagulation factors exert their pleiotropic effects in pathophysiology remains one of the major challenges in the field. This overview presents current insight in how the main coagulation factors might induce inflammation. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:30 / 37
页数:8
相关论文
共 88 条
[1]   Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].
Abraham, E ;
Reinhart, K ;
Svoboda, P ;
Seibert, A ;
Olthoff, D ;
Dal Nogare, A ;
Postier, R ;
Hempelmann, G ;
Butler, T ;
Martin, E ;
Zwingelstein, C ;
Percell, S ;
Shu, V ;
Leighton, A ;
Creasey, AA .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089
[2]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]   Chemokines: Leucocyte recruitment and activation cytokines [J].
Adams, DH ;
Lloyd, AR .
LANCET, 1997, 349 (9050) :490-495
[4]  
ALTIERI DC, 1994, J BIOL CHEM, V269, P3139
[5]  
ALTIERI DC, 1990, J IMMUNOL, V145, P246
[6]   Unraveling severe sepsis - Why did OPTIMIST fail and what's next? [J].
Angus, DC ;
Crowther, MA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :256-258
[7]  
Anrather D, 1997, J IMMUNOL, V159, P5620
[8]   Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2 [J].
Bergum, PW ;
Cruikshank, A ;
Maki, SL ;
Kelly, CR ;
Ruf, W ;
Vlasuk, GP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :10063-10071
[9]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[10]   RECOMBINANT TUMOR-NECROSIS-FACTOR INDUCES PROCOAGULANT ACTIVITY IN CULTURED HUMAN VASCULAR ENDOTHELIUM - CHARACTERIZATION AND COMPARISON WITH THE ACTIONS OF INTERLEUKIN-1 [J].
BEVILACQUA, MP ;
POBER, JS ;
MAJEAU, GR ;
FIERS, W ;
COTRAN, RS ;
GIMBRONE, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4533-4537